The major neutralization antigen VP7 of rhesus rotavirus (RRV) was expressed in a baculovirus recombinant system. The expressed VP7 showed the same molecular mass as native VP7, and was recognized by hyperimmune sera as well as neutralizing and non-neutralizing monoclonal antibodies (MAbs) raised against RRV. Intraperitoneal administration of the expressed VP7 in mice elicited the production of serum antibodies which were able to immunoprecipitate VP7 from RRV-infected cell lysates and to neutralize the virus in vitro. Sera from immunized mice competed for binding to RRV in an ELISA with both neutralizing and non-neutralizing MAbs specific for VP7. Using a passive protection model of rotavirus disease, vaccination of mice with the recombinant VP7 induced partial protection from infection. These results suggest that the baculovirusexpressed VP7 may be useful in priming a protective immune response to rotavirus infection.
Introduction
Rotavirus is a leading cause of severe gastroenteritis in infants and young children throughout the world (De Zoysa & Feachem, 1985; Kapikian & Chanock, 1990) . In developing countries, rotavirus infection is also associated with high infant mortality. Estimates suggest that 5 x 105 to 1 × 10 ° deaths might be prevented annually by an effective rotavirus vaccine.
The most extensively evaluated oral rotavirus vaccines for human use are either animal strains or reassortant viruses which are attenuated in humans (Ward et al., 1986; Clark et al., 1986; Anderson et al., 1986; Vesikari et al., 1985; Flores et al., 1988; Midthun et al., 1985; Vesikari, 1993) . Although promising, such vaccines have not been proven to consistently confer high levels of effective protection from rotavirus disease (Green et al., 1990; De Mol et al., 1986; Hanlon et al., 1987) . Furthermore, the rhesus rotavirus (RRV) vaccine causes low grade fevers in 25 % of vaccinees. Aside from host factors, the incomplete success of live rotavirus vaccine trials may reside in the inability of vaccine strains to * Author for correspondence. Fax +39 6 4453369. e-mail delta @virusl.iss.infn.it induce a cross-reactive neutralizing immune response to antigenically diverse rotaviruses that circulate in different areas of the world.
The recent development of a dual serotyping nomenclature for rotaviruses acknowledges the contributions of both outer capsid proteins, VP4 and VP7, to viral neutralization and protection. The knowledge that both VP4 and VP7 are involved in viral neutralization (Hoshino et al., 1988; Greenberg et al., 1983a) has broadened the scope of antigens that must be considered when designing rotavirus vaccines. Recombinant VP4 and VP7 antigen expression systems have been used to investigate the role of individual proteins in eliciting protective immune responses in animals in an effort to stimulate broadly cross-reactive immune responses (Offit & Blavat, 1986; Andrew et al., 1987; McCrae & Corquodale, 1987; Francavilla et al., 1987; Arias et al., 1986) . Among several studies on the expression of rotavirus surface antigens, the baculovirus-expressed VP4 from RRV was shown to induce both moderate levels of neutralizing antibodies to the homologous virus and low levels of neutralizing antibodies to heterologous rotaviruses. In addition, the recombinant protein effectively protected suckling mice from homologous and heterologous rotavirus disease in a passive-transfer model of immunity (Mackow et al., 1989 In this study, RRV VP7 was expressed in a baculovirus expression system and its antigenic characteristics were assayed using neutralizing and non-neutralizing specific MAbs. The ability of baculovirus-expressed VP7 to stimulate a neutralizing immune response was also investigated in both neutralization assays and in a murine passive immunization model.
Methods

Cells and viruses.
Rotaviruses were grown on a continuous monkey kidney cell line, MA104, as previously described (Shaw et al., 1985) . Stock rotavirus strains used in focus reduction neutralization (FRN) assays were RRV, simian (G3); OSU, porcine (G5); Gottfried, porcine (G4), NCDV, bovine (G6); and the human strains Wa (G1), DS1 (G2) and Price (G3). Autographiea caliJbrniea nuclear polyhedrosis virus (AcNPV) (Baculoviridae) strain E2, and recombinant baculoviruses expressing VP7 were grown on Spodoptera frugiperda (Sf9) cells in Excell 400 medium (J.R. Scientific).
Recombinant baculovirus construction and VP7 expression. The recombinant baculovirus expressing VP7 was constructed using a strategy previously described for RRV VP8 (Fiore et al., 1991) . Gene 9-specific positive-strand (bases 48 to 75) and negative-strand (bases 1040 to 1062) DNA primers were used for PCR amplification of the RRV gene segment 9 cloned into plasmid pUC935.
Baculovirus shuttle plasmid pACYM1 (Matsuura et al., 1987) was linearized by BamHI digestion, filled with T4 DNA polymerase in the presence of dXTPs (0"2 mM) and blunt-end ligated to the amplified DNA. After transformation of XL 1-B competent cells, the plasmid was screened for orientation by enzymatic digestion and sequencing (Sanger et al., 1977) . Sf9 cells were co-transfected with a mixture of the VP7 plasmid and AcNPV genomic DNA at a ratio of 10:1, or 1 : 1, by the lipofection method (Feigner et al., 1987) , and were incubated at 28 °C for 5-6 days. Recombinants in which homologous recombination replaced the polyhedrin gene with VP7 were selected by identifying occlusion-negative plaques with an inverted microscope, and were plaque-purified three times.
Expression of recombinant VP7 in infected cells was confirmed by immunocytochemical staining. Sf9 cells were infected with wild-type or VP7 recombinant baculovirus at approximately 1 p.f.u./cell and incubated at 28 °C for 4 days. The medium was removed and cells were fixed with ice-cold methanol or 2 % paraformaldehyde in phosphatebuffered saline (PBS) for 10 min at room temperature. Paraformaldehyde-fixed cells were permeabilized with 0-1% Triton X-100 in PBS for 5 rain. Intracytoplasmic expressed VP7 was detected by light microscopy after immunoperoxidase staining with VP7-specific MAbs (Harlow & Lane, 1988) .
Selection of baculovirus expressing the highest level of VP7 protein was performed by SDS-15 % PAGE (Laemmli, 1970) and Co omassie blue staining of recombinant or wild-type AcNPV infected cell sonicates.
Enzyme-linked immunosorbent assay (ELISA).
For ELISA determination of expressed VP7, a solid-phase assay was used essentially as described by Shaw et al. (1985) . AcNPV or AcNPV-VP7 infected Sf9 cells were resuspended in 50 mM-Tris-HC1 (pH 9) in the presence of PMSF and sonicated for 30 s at 30 W. Cell extracts were diluted 1 : 100 in PBS, and coated onto Immunolon-2 microtitre ELISA plates (Dynatech). After incubation at 4 °C overnight, wells were blocked with 1% BSA in PBS for 2 h at 37 °C, and rinsed with PBS containing 0"05% Tween 20. MAbs specific for RRV VP7 (Greenberg et al., 1983 b; Shaw et al., 1986 ) and a hyperimmune guinea pig antiserum to RRV diluted 1 : 1000 in 0.5 % BSA in PBS were then added, and plates were incubated for 2 h at 37 °C. After washing with PBS-Tween 20, plates were reacted with a 1 : 1000 dilution of alkaline-phosphataseconjugated goat antibody to either mouse or guinea pig IgG for 1 h at 37 °C followed by incubation with 1 mg/ml p-nitrophenyl phosphate in 10 mM-diethanolamine buffer (pH 9.5) at 37 °C for 1 h. The A405 was read in a Bio-Rad ELISA reader.
Radioimmunoprecipitation (RIPA).
Sf9 cells were infected with VP7 recombinant or wild-type AcNPV baculoviruses for 72 h and radiolabelled overnight with 50 laCi/ml [35S]methionine (Tran35S label, ICN) in methionine-free medium. Cells and media were pelleted at 3000 g at 4 °C for 10 min. The cell pellets were lysed in RIPA buffer (0'3 M-NaC1, 1% sodium deoxycholate, 1% Triton X-100, 0.1% SDS, 1 mM-PMSF) for 30 rain at 4 °C. Lysates were clarified by centrifugation at 100000 g and the supernatants were used for immunoprecipitation experiments as previously described (Greenberg et al., 1983b) . To prepare ~sS-labelled rotavirus proteins, MA104 cell monolayers were infected at an m.o.i, of 5 with trypsin-activated RRV in serum-free medium. After 3 h, the medium was replaced with methionine-free Eagle's minimal essential medium containing 50 ~tCi/ml [zsS]methionine. At 12 h postinfection, the medium was discarded and cells were lysed as described above for use in immunoprecipitation assays.
Haemagglutination-inhibition assay. This was performed as described by Kalica et al. (1983) . Briefly, 0.025 ml of serial twofold dilutions of mouse sera in PBS supplemented with 0.5 % BSA were mixed with equal volumes of RRV suspension containing 8 haemagglutinating units in 96-well plates. In particular assays, baculovirus-expressed RRV VP4 (Mackow et al., 1989) was used as the haemagglutinin. After incubation for 1 h at room temperature, 0.05 ml of group O human erythrocytes at a concentration of 0.4 % in PBS-BSA was added to each reaction. HI titres were calculated as the reciprocal of the highest serum dilution preventing haemagglutination.
Immunization of mice. CD-1 female mice (4 weeks old) were obtained from the Portage facility of Charles River Biolabs and were housed in isolation cages throughout experiments. Animals were screened on arrival for serum antibody to rotavirus. All sera were negative for preexisting rotavirus antibody at a dilution of 1:50 by ELISA and immunoprecipitation of radiolabelled rotavirus proteins. Mice were immunized intraperitoneally with 0.2 ml of clarified sonic extracts from Sf9 cells infected with either AcNPV or AcNPV-gene 9 or from uninfected Sf9 cells in a 50:50 mixture of complete Freund's adjuvant. Recombinant VP7 protein in 0"2 ml of inoculum was estimated to be approximately 25 lag (about 2 % of total protein) by comparison with protein standards by SDS-PAGE and Coomassie blue staining. Each Monolayers were lysed with RIPA buffer and centrifuged at 3000 r.p.m, for 15 min. Supernatants were precipitated with VP7-specific MAbs 60, 159, 129, 96, 5H3 and 4F8; VP4-specific MAbs 2G4 and 7A12 were run as controls. Guinea-pig hyperimmune anti-RRV serum (HIGP) was used to precipitate Sf9, wild-type AcNPV, VP7-AcNPV lysates and RRV lysates as indicated. Immunoprecipitated proteins were resolved by 15 % PAGE, as described in Methods. M, molecular mass markers.
group of mice was boosted four to five times at 4 week intervals with the same dosage of the immunogens in incomplete Freund's adjuvant and were bled 2 weeks after each boost.
Mouse protection studies. Serum antibody and protection studies were performed on two separate sets of CD-1 mice. Intraperitoneal hyperimmunization (four to five immunizations) of the first set of mice used for antibody neutralization assays caused peritoneal inflammation which rendered the mice unsuitable for mating. A second set of CD-1 mice were therefore immunized as described above except for being boosted only twice. These mice were used for the protection study and had HI and neutralizing serum titres lower than mice from the first group. Immunized dams were bred with CD-1 males at 15-20 weeks of age. Dams were boosted subcutaneously with 5 gg of protein before breeding. Rotavirus challenge of 4-5 day-old suckling mice from both control and immunized dams was done by oral inoculation with RRV (2 x 107 p.f.u., corresponding to approximately 100 50 % diarrhoeagenic doses) in 0' 1 ml of medium through a gavage needle. This dose of virus caused diarrhoea in 90 % of inoculated normal animals. Pups were monitored daily for onset of diarrhoea (determined by the appearance of liquid stools upon gentle abdominal palpation).
Focus reduction neutralization assays (FRN). An immunoperoxidase
staining technique for detecting infected cells was used in a neutralization assay as described previously (Shaw et al., 1985 (Shaw et al., , 1986 ).
Approximately 200 focus-forming units of the specified rotavirus strain was mixed with serial dilutions of serum taken from mice immunized with recombinant VP7 or control cell extracts. The mixtures were incubated for 60 min at 37 °C and inoculated onto MA104 cells in 96-well plates. Infected cells were fixed 18 h later with cold methanol and stained as previously described (Shaw et al., 1986) . Titres are expressed as the inverse dilution resulting in a 60 % or higher reduction in the number of infected MA104 cells.
Epitope competition binding assay. RRV from tissue culture fluid was partially purified by extraction with 1,1,2-trichlorotrifluoroethane and pelleting through a 20 % sucrose cushion in a Beckman SW 41 rotor at 35000 r.p.m, for 90 min at 4 °C. The virus pellet was resuspended in PBS supplemented with 2 mM-CaC12, and used to coat microtitre ELISA plates. Plates were blocked with PBS-5 % fetal bovine serum before use. VP7-specific MAbs were purified by protein G affinity chromatography, and biotinylated as previously described (Shaw et al., 1986) . The competition ELISA was carried out according to the method of Shaw et al. (1986) . Briefly, serial twofold dilutions of mouse sera in PBS-1% BSA were added to RRV-coated ELISA plates. After incubation for 1 h at room temperature, biotinylated MAb (555 ng) was added to each well. The concentration of each biotinylated antibody was adjusted to give an A490 reading of approximately 1.0 in the absence of competition, and ranged between 5 and 25 ng/ml depending on the antibody used. After incubation for 1 h at 37 °C, the plates were washed four times with PBS~0"I% Tween 20, and avidin-horseradish peroxidase conjugate was added. After 30 min at 37 °C, the plates were washed and the substrate, o-phenylenediamine in 50 mM-citrate-phosphate buffere (pH 5'3) with hydrogen peroxide, was added. After 30 min at room temperature, the reaction was stopped by the addition of 1-5 M-stflphuric acid, and the plates were read on an ELISA reader at a wavelength of 490 nm. Competition by a test serum dilution was considered as significant when the absorbance generated by the biotinylated MAb was reduced by at least 50 %.
Results
Antigenicity of the baculovirus-expressed VP7
A ptasmid transfer vector containing the RRV VP7 gene was constructed under the control of the baculovirus polyhedrin promoter. Polyhedrin-minus viruses were initially screened for VP7 expression by immunostaining with a VP7-specific MAb (MAb 60) of either the infected cells or dot blots of sonicated cellular extracts (data not shown). Maximum VP7 expression was found to occur between 72 and 96 h post-infection. The expressed VP7 was also found in the tissue culture media as assayed by immunoprecipitation, although it appeared to be primarily localized within the cells (data not shown).
The cell-associated VP7 was tested by immunoprecipitation with hyperimmune anti-RRV serum and VP7-specific MAbs (Fig. 1) . Based on the migration on SDS-polyacrylamide gels under denaturing conditions the expressed protein appeared to be similar in size to the native VP7 from RRV-infected cell lysates. The AcNPVinfected SO cell lysates did not contain a protein of this size. VP7 was immunoprecipitated by the anti-RRV polyclonal sera as well as by two non-neutralizing MAbs (129 and 60) and two neutralizing MAbs (96 and 5H3). VP7-specific neutralizing antibodies 4F8 and 159 and VP4-specific neutralizing MAbs (2G4 and 7A12) did not immunoprecipitate the recombinant VP7. Baculovirusexpressed VP7 was also recognized in an ELISA by hyperimmune antisera to VP7 and MAbs 60, 129, 5H3, 4F8, 96, 57.8 and 159 (Table 1) . MAb 159 failed to immunoprecipitate recombinant VP7, but recognized VP7 in ELISA. The VP4-specific MAbs (2G4 and 7A12) failed to recognize recombinant VP7.
Characterization of antisera produced to expressed VP7
To determine the immunogenicity of the baculovirusexpressed VP7 protein, six CD-1 mice were immunized with the VP7 sonicates as described in Methods. The mouse sera showed HI and FRN titres against RRV ranging from 1 : 320 to 1 : 2560 and from 1 : 400 to 1 : 6400, respectively (Table 2) . Control mice immunized with 
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ControlAcNPV protein 1 < 10 < 100 < 100 < 100 < 100 < 100 < 100 < 100 < 100 2 <10 <100 <100 <100 <100 <100 <100 <100 <100 * Haemagglutination inhibition (HI) titres are expressed as the reciprocal of the serum dilution required to inhibit haemagglutination (HA) by 4 to 8 HA units of RRV. uninfected Sf9 cell sonicates or with AcNPV-infected cell sonicates had HI and F R N serum titres of < 1 : 10 and < 1:100, respectively. Sera from the immunized mice recognized VP7 by immunoprecipitation using metabolically labelled RRV-infected cell lysates, but not VP4 or other RRV proteins, confirming that the observed neutralizing activity was VP7-specific (Fig. 2) . The presence of anti-VP4 antibodies in these mice was also excluded by the inability of their sera to HI when tested against a baculovirus-expressed RRV VP4 (data not shown). Sera from the immunized mice were also tested by FRN assays for the presence of cross-reactive neutralizing antibodies against different animal and human rotavirus serotypes. Mice immunized with the expressed RRV VP7 developed neutralizing antibodies that reacted only with RRV (Table 2) ; no reaction was seen to the human G3 strain, Price.
Protection study
Three CD-1 female mice were immunized with baculovirus-expressed VP7 to evaluate the ability of the recombinant VP7 to elicit an antibody response against homologous rotavirus challenge in a passive protection model. The VP7-immunized mice had HI titres of 1 : 100 G2  6  100  640  0  G3  6  400  640  50  G4  14  200  640  21  Total  26  23 Control AcNPV protein E1 13 < 100 < 40 0 E2 10 < 100 < 40 0 SO cells F1 8 < 100 < 40 0 F2 11 < 100 < 40 0 F3 13 < 100 < 40 0 * Maternal HI titre at time of pup challenge. The titre is expressed as the reciprocal of the serum dilution required to inhibit H A of 4 to 8 HA units of RRV.
t Focus reduction neutralization (FRN) data represent the reciprocal of the serum dilution resulting in a reduction of 60 % or more in the number of infected MA104 cells.
1~ Protection against R R V challenge expressed as the percentage of the number of pups with no diarrhoea over the total number of pups.
to 1" 400 and F R N titres of 1 : 640 against RRV (Table 3) . When the neonates of the VP7-immunized dams were challenged with RRV, protection ranged from 0 % to 
400
* Fourfold or greater increases in blocking or neutralization titres of the postvaccination sera compared with the prevaccination sera are indicated in bold type.
50 % with an overall protection rate of 23 % (Table 3 ). All 32 controls had HI titres of < 1 : 100 and FRN titres of < 1:40 and none were protected from diarrhoea following RRV challenge. No difference was shown in severity or duration of diarrhoea between the pups from the VP7-immunized and unimmunized dams.
Competitive binding studies
Sera obtained from four of the first set of CD-1 mice were analysed in a competition binding ELISA with three characterized VP7-specific neutralizing MAbs (159, 4F8 and 5H3) and one VP7-specific non-neutralizing MAb (MAb 60). Three mouse sera were found to be able to compete for binding with the neutralizing MAbs (Table 4) . Competition was observed between the sera and MAbs 159 and 4F8 which define a major neutralization domain on the VP7 protein. Binding of these biotinylated MAbs was virtually abolished at serum dilutions as high as 1 : 640. Higher serum concentrations were required for two of the sera to compete with MAb 5H3. The mouse sera also competed with the nonneutralizing VP7 MAb 60, whereas no competition was observed with the VP4-specific neutralizing MAb 2G4 (data not shown). The competition of the mouse sera with the binding of MAbs 159 and 4F8 correlated with their ability to neutralize RRV in FRN assays (Table 4) .
The same analysis was also performed on sera from dams used in protection experiments. Competition could not be clearly established at the serum dilutions used, which is probably accounted for by the lower level of antibody elicited in this second group of mice.
Discussion
We have expressed the RRV outer capsid protein VP7 using a recombinant baculovirus expression system. The recombinant protein appears to have the same molecular mass as the native VP7 present in RRV-infected cell lysates, and retains the ability to react with both polyclonal sera and MAbs specific for native VP7. Of particular interest is the recognition of the expressed VP7 by MAbs directed at both the A and B neutralization domains described on this protein by Shaw et al. (1986) ; these MAbs appear to neutralize RRV with high efficiency in cell cultures (Ruggeri & Greenberg, 1991) , and have been proven to be protective in vivo in a mouse model (Offit et al., 1986b) .
The failure of the VP7 in immunized mice to elicit a heterotypic response to other human or animal rotavirus strains is not surprising since VP7 defines the rotavirus serotype. In addition, sera from these mice failed to neutralize one human rotavirus, strain Price, belonging to the same G serotype as RRV, suggesting that immunization with the expressed VP7 appears to elicit only strain-specific antibody. Similar 'monotypic' VP7 responses have also been demonstrated by others (Coulson et al., 1987) .
A murine passive protection assay for testing the ability of colostrum from rotavirus immunized dams to protect pups from diarrhoeal disease has been reported (Offit et al., 1986a, b) . This model also has been used to show that baculovirus-expressed RRV VP4 can protect against homologous and heterologous virus challenge . We have used the passive protection model to evaluate the protective immune response to heterologous RRV challenge in dams immunized with recombinant VP7. The mice showed only a low level antibody response to RRV as measured by FRN and HI. This finding is consistent with the neutralizing serum antibody response produced in mice immunized with SAll rotavirus VP7 expressed in baculovirus (McGonigal et al., 1992) . Two of the three litters of pups from dams immunized with baculovirusexpressed RRV VP7 were partially protected from disease. These results are consistent with recent studies demonstrating that passive protection can be partially conferred by VP7 of bovine rotavirus expressed in baculovirus (Redmont et al., 1993) . The FRN results against different rotavirus serotypes (Table 2) seem to suggest that vaccination with VP7 from a particular rotavirus strain would not confer protection to heterologous viruses. To induce a broad spectrum protective immunity it may thus be necessary to combine recombinant VP7 proteins from different G serotype strains in a single vaccine.
The relatively low immunogenicity of VP7 expressed in baculovirus and other recombinant systems may be because the native VP7 epitopes of immunological importance are dependent on the protein conformation. Complex nonlinear epitopes of the VP7 protein may be affected by interactions with VP4 and/or VP6. The conformational epitopes absent in single expressed proteins might be reconstituted by co-expressing VP7 with VP4 and/or VP6 and by the inclusion of Ca 2+ cations in the media (Dormitzer et al., 1992 (Dormitzer et al., , 1994 . Recombinant baculovirus systems seem well suited for this purpose. Assembly of virus-like particles containing bovine rotavirus VP6, VP4 and VP7 has been reported, and the assembled particle with VP7 was shown to confer greater protection to virus challenge than single expressed VP7 (Redmont et al., 1993; Crawford et al., 1994) .
Although our immunization of mice with expressed VP7 only yielded a partial protection in vivo, the results obtained from the first set of mice suggest that antigenic domains involved in neutralization and protection are at least partially conserved in the expressed VP7 and properly presented to the immune system. In fact, sera from these mice that were repeatedly boosted with the recombinant protein were able to efficiently compete for binding of selected MAbs to RRV virions in an ELISA assay. Competition was complete with both the nonneutralizing MAb 60 and the neutralizing MAbs 4F8 and 159. The latter are directed at a major neutralization epitope of VP7 and have been proven to passively protect infant mice from diarrhoea when orally administered prior to RRV challenge (Shaw et al., 1986) . The reduced competition shown by the sera with respect to the neutralizing MAb 5H3 may reflect the inability of the expressed VP7 to induce a specific immune response against the epitope recognized by this MAb. The noted effect may be explained by partial steric hindrance of mouse serum antibodies with the MAb 5H3 specific epitope. In fact, it has been shown that MAbs 159 and 4F8 can partially inhibit binding of biotinylated MAb 5H3 to RRV in competition experiments (Shaw et al., 1986) . Competitive activity in mouse sera increased upon repeated cycles of immunization and correlated with in vitro neutralization titres.
Even though the immunogenicity of baculovirusexpressed VP7 does not seem to be as high as that shown by expressing the protein on the cell surface of adenovirus and vaccinia virus (Andrew et al., 1990 (Andrew et al., , 1992 Both et al., 1993) , the insect system has the advantage of being a particularly safe tool for the preparation of human vaccines. In order to improve protein immunogenicity, use of alternative carriers or adjuvants should be evaluated in further studies. Alternatively, larger amounts of VP7 might be produced and used for immunization. It may also be useful to stabilize the conformation of VP7 in order to properly present the antigenic epitopes, perhaps by assembly of particles. For active protection, however, immunization strategies targeted to the gastrointestinal tract may well be required.
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